When the reported disappearance of Guo Guangchang, chairman of Fosun Group, rippled through markets, it exposed the “key man” risk for investing in Chinese companies.

Buying Australia’s leading health supplement brand matches Fosun’s global ambitions — and could also help the target boost its China sales.

A strategic divestment and one of the first non-property high-yield Chinese bond sales to come to market since the Covid-19 lockdown secure the Chinese conglomerate’s war chest.

Fosun outbid several rivals after agreeing to pay a revised €459.8 million for the 96% stake in Espirito Santo Saude.

CEO Liang Xinjun talks to FinanceAsia about the shift from a Chinese industrial conglomerate to a global investment group. The interview comes as Fosun launches a rights offering.

Debt-laden Fosun International increases size of three-year loan to $800 million amid keen interest from Asian lenders.

Fosun International’s bid for English football club Wolverhampton Wanderers is atypical for the conglomerate.

The privately-held drug maker raised $296 million from a fully-upsized placement of new H-shares, marking just the second time in nearly three years that a Hong Kong-listed company has sold new shares through a block sale.

CEO Liang Xinjun tells FinanceAsia that Fosun will narrow its M&A focus. He spoke as new details emerged on the reason behind the chairman's disappearance.

Bank of China and ICBC are expected to arrange Fosun’s €500 million bridge loan to acquire the insurance arm of Portugal’s Caixa Geral de Depósitos